NEWARK, Calif., May 28, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief
Executive Officer, will present at two upcoming virtual healthcare
investor conferences.
Presentation details:
Event: Jefferies Virtual Healthcare Conference
Date: Wednesday, June 3, 2020
Time: 10:30 a.m. EDT
Event: Raymond James Human Health Innovations Conference
Date: Thursday, June 18,
2020
Time: 1:40 p.m. EDT
Live and archived webcasts of the Jefferies and Raymond James
presentations can be accessed by visiting the Investors section of
the Protagonist Therapeutics website at
http://investors.protagonist-inc.com/.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms for
patients. The Company currently has three clinical-stage assets.
PTG-300 is an injectable hepcidin mimetic in development for the
treatment of polycythemia vera and hereditary hemochromatosis.
PTG-200 is an orally delivered, gut-restricted, interleukin-23
receptor specific antagonist peptide in development for the
treatment of inflammatory bowel disease, with Crohn's disease as
the initial indication. The Company has a worldwide license and
collaboration agreement with Janssen Biotech, Inc., for the
development of PTG-200. PN-943 is an orally delivered,
gut-restricted alpha-4-beta-7 integrin specific antagonist peptide
in development for the treatment of inflammatory bowel disease,
with ulcerative colitis as the initial targeted indication.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
View original
content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-two-upcoming-healthcare-investor-conferences-301066740.html
SOURCE Protagonist Therapeutics, Inc.